Merit Medical Systems, Inc. · NASDAQ:MMSI
Merit Medical Systems — Merger or Acquisition (July 2016)
13 slides from Merit Medical Systems's merger presentation, Jul 6, 2016
Slide 1: Acquisition of DFINE
ACQUISITION OF Hep FINE Targeted Vertebral Solutions MRT
Slide 2: Disclosure Regarding Forward-Looking Statements
2 DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS This presentation includes “forward-looking statements” as defined within applicable securities laws and regulations. All statements in this presentation, other than statements of historical fact, are “forward-looking statements,” including projectio
Slide 3: About DFINE
3 Founded in 2004, DFINE is dedicated to changing the lives of patients debilitated by pain through advancements in minimally invasive technology to treat vertebral pathologies. DFINE has developed and commercialized a full line of next generation products and therapies for the treatment of vertebra
Slide 4: Next Generation Products
NEXT GENERATION PRODUCTS Vertebral Compression Fractures Tumors Metastatic Spinal
Slide 5: Targeted approach with ultra-high viscosity cement
5 Combines a targeted approach and ultra-high viscosity cement to repair compression fractures and minimize extravasation in the vertebrae.
Slide 6: StabiliT MX
6 StabiliT MX provides a targeted, bone-sparing cavity creation approach to vertebral augmentation with DFINE’s patented cement preparation and controlled delivery of high-viscosity cement.
Slide 7: StabiliT VP
7 StabiliT VP combines DFINE’s patented simple cement preparation with the controlled delivery of high-viscosity cement. Simplicity Speed Control
Slide 8: STAR System
8 With the STAR System, physicians have the control to navigate and target site-specific ablation zones and monitor real-time ablation zone development within the vertebral body.
Slide 9: Strong Strategic Fit
9 STRONG STRATEGIC FIT PRESENT • Development and commercialization of more advanced products and therapies which enhance growth and profitability • Moving to a disease-centric, ‘follow the patient’ model • Evaluate and enter complementary segments leveraging both technology platforms and commercial
Slide 10: Introducing Interventional Oncology & Spine
10 INTRODUCING INTERVENTIONAL ONCOLOGY & SPINE • Tumor Management and Spine Focus • Complementary technologies, products, and physician base • Strong understanding and current position with existing physicians and healthcare institutions • 80% customer compatibility rate IOS
Slide 11: Addressable Market Pre and Post Acquisition
11 Pre Acquisition Addressable Market $577 Million Post Acquisition Addressable Market $2.3 Billion INTERVENTIONAL ONCOLOGY & SPINE
Slide 12: Transaction Overview
12 TRANSACTION OVERVIEW IMPACT • Revenues for DFINE were $33.4 million in 2015 • Remain committed to 3-year plan and revenue growth of 8% year on year • The transaction is expected to be neutral on an EPS non-GAAP basis in 2016 and accretive in 2017 ($0.05 - $0.08) • Accretive to gross margin on a n
Slide 13: 13
13
Merit Medical Systems — Merger or Acquisition (July 2016) on 6ix